Open an account

Charles River Laboratories International

CRL · NYSE

$315.45+$15.43 (+5.14%)TodayMarket closed ·
Prev close $300.02

About CRL

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Employees
18,300
Headquarters
Wilmington, Massachusetts
Listed
Jun 23, 2000
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
criver.com

CRL key statistics

Market cap
14.32B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
975.92K
Volume
1.27M
Open price
$305.93
High today
$317.59
Low today
$304.00
52 Week high
$333.30
52 Week low
$146.20

Charles River Laboratories International (CRL) at a glance

Charles River Laboratories International (CRL) last traded at $315.45, with a market cap of 14.32B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $304.00 and $317.59. The current price is 3.8% above the day's low and 0.7% below its high.

Volume so far is 1.27M shares, above the average of 975.92K shares a day.

Over the past year Charles River Laboratories International has ranged from $146.20 to $333.30, and now sits 90% of the way up that range.

Charles River Laboratories International met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $3.02 per share against an estimate of $2.76.

The average analyst price target is $307.39, 2.6% below the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

79%of 14 analyst ratings say Buy
  • Buy78.6%
  • Hold21.4%
  • Sell0.0%
Price target · 19 analystsAvg $307.39
Low
$147.27
Now
$315.45
High
$374.85

CRL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 7.9% on average.

  1. Q3 FY24: reported $2.59 per share against an estimate of $2.45
  2. Q4 FY24: reported $2.66 per share against an estimate of $2.56
  3. Q1 FY25: reported $2.34 per share against an estimate of $2.10
  4. Q2 FY25: reported $3.12 per share against an estimate of $2.52
  5. Q3 FY25: reported $2.43 per share against an estimate of $2.36
  6. Q4 FY25: reported $2.39 per share against an estimate of $2.37
  7. Q1 FY26: reported $2.06 per share against an estimate of $1.96
  8. Q2 FY26: reported $3.02 per share against an estimate of $2.76

CRL news

  • Press releaseBusiness Wire

    Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

  • Press releaseBusiness Wire

    Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call

  • Press releaseBusiness Wire

    Charles River and Autolomous Partner to Transform Laboratory Execution Systems

  • Piero Cingari

    S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today

  • Press releaseBusiness Wire

    Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day

  • Press releaseBusiness Wire

    Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

  • Press releaseBusiness Wire

    Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

  • Press releaseBusiness Wire

    Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

Similar companies

Companies in the same industry as Charles River Laboratories International

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.